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Abstract
Background Severe postoperative loss of vision has been
occasionally reported as a rare complication of retrobulbar
anesthesia, and several possible causes have been proposed
in the literature. In this work, our own and other
investigators’ experiences with these complications are
surveyed with a view to identifying its pathophysiology.
Patients This observational case series refers to six patients
who presented during a 3-month period with occlusion of
either the central artery itself (n=3) or a branch thereof (n=
3) 2–14 days after uneventful vitreoretinal surgery follow-
ing retrobulbar anesthesia with a commercial preparation of
mepivacaine (1% Scandicain®, Astra Chemicals, Sweden)
containing methyl- and propyl parahydroxybenzoate as
preservatives.
Results Three of the patients carried risk factors, which
were medically controlled. In three individuals, vasoocclu-
sion was observed after a second vitreoretinal intervention,
which was performed 3–12 months after uneventful
primary surgery. Good visual recovery was observed in
only one instance.
Conclusions In patients who were anesthetized with
preservative-free mepivacaine, no vasoocclusion occurred.
In individuals who were anesthetized with mepivacaine
containing the preservatives methyl- and propyl para-
hydroxybenzoate, a tenfold increase in the incidence of
eyes requiring re-operation was documented, with a 2- to
14-day lapse in the onset of vasoocclusion. These findings
reveal a possible implication of preservatives contained in
the local anesthetic solution for the vasoocclusive events.
Due to this potential hazard, the use of preservative-free
preparations of local anesthesia in ocular surgery is
emphasized in order to prevent this sight-threatening
complication.
Keywords Retinal vascular occlusion .Mepivacaine .
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Introduction
In anterior-segment surgery, retrobulbar anesthesia has been
largely superseded by topical narcosis. To avoid the
necessity for general anesthesia in vitreoretinal surgery,
blockage of the retrobulbar nerve using Atkinson’s tech-
nique is now widely implemented to effect akinesia and
analgesia. Complications of this procedure (e.g., hemor-
rhage, iatrogenic injection of the local anesthetic into the
optic-nerve sheath or perforation of the ocular globe) are
rare, but may lead to a dramatic and permanent loss of
vision. In this observational study, we describe a case series
of six patients who developed retinal-artery occlusion after
uneventful pars-plana vitrectomy under conditions of
retrobulbar anesthesia. On the basis of our own and other
investigators’ experiences with this complication, we
discuss its possible etiology, including an anesthetic-
induced vasospasm and the neurotoxicity of preservative
agents.
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Case series
During a 3-month period, six patients presented with acute
visual disturbance 2–14 days after uneventful vitrectomy:
with air for the treatment of either an epiretinal membrane (n=
1) or vitreous hemorrhaging (n=1); with a 15% SF6−gas
tamponade for a macular hole (n=1); and with air after the
removal of silicone oil in conjunction with successful retinal
detachment surgery for either PVR (n=2) or a persistent
macular hole (n=1). Blockage of the retrobulbar nerve using
Atkinson’s technique was achieved by injecting 3.5 ml of a
commercial preparation of mepivacaine (1% Scandicain®,
Astra Chemicals, Sweden), which contained methyl- and
propyl parahydroxybenzoate as preservatives. The drug
solution (which contained no adrenalin) was injected 30
min prior to the onset of surgery in each case. Uneventful
vitreoretinal surgery (involving a 23-gauge needle micro-
incision) was completed within 30–60 min without intra-
operative fluctuations in intraocular pressure (IOP). On the
1st postoperative day, none of the operated eyes evinced
signs of irregularities in retinal perfusion, and the IOP
followed a normal course in each case. No functional
abnormalities were reported. Between the 2nd and the 14th
postoperative days, each of the patients experienced a central
loss of vision, which was not related to the presence of either
residual air or SF6-gas. Examination revealed a normal IOP
(11–19 mm of Hg) in all instances. The anterior segment was
quiet, except for mild conjunctival hyperemia and, in two
cases, subconjunctival hemorrhaging at the site of sclerot-
omy. Retinal biomicroscopy revealed hemorrhagic ischemic
retinopathy and vascular occlusion in all instances.
The decrease in visual acuity was subsequently revealed to
be due to occlusion of either the central retinal artery (n=3) or
a branch thereof (n=3) (Figs. 1 and 2). As postoperatively
assessed by carotid Doppler sonography, echocardiography,
transesophageal echography, and 24-h electrocardiography,
no critical systemic risk factors for vasoocclusive events
were identifiable in any of the subjects. Nevertheless,
three of the patients had a history of treated arterial
hypertension; one of these suffered from diabetes
mellitus, and one had undergone prophylactic treatment
with aspirin for cardiac problems after surgery for an
aortic aneurysm 23 years earlier (Table 1). Beyond
confirmation of an optimal therapy of their preexisting
underlying diseases, all patients received (after exclusion
of contraindications) a local IOP lowering therapy with
timolol 0.5% for 10 days, aspirin 100 mg/day for
3 months, and a retard preparation of nifedipine
20 mg/day for 1 month. One year after surgery, visual
acuity was poor in five of the patients (20/200 in four
individuals; light perception in one) and excellent in one
(20/20).
Discussion
Occlusion of the retinal artery after intraocular surgery with
anesthesia of the retrobulbar nerve has been reported in
small cohorts of patients during the past few decades
(Table 1). Although no direct explanation for the vaso-
occlusive event was furnished in the pertinent publications,
various causative factors were discussed, including iatro-
genic injuring of the optic nerve during the injection of the
local anesthetic and traumatic retrobulbar hemorrhage with
an ensuing increase in IOP or a compression of the ocular
globe [1–4]. Hørven et al. demonstrated that the anesthetic
solution itself could cause a decrease in blood flow within
the ophthalmic artery by exerting a vasoconstrictive effect
[5]. Klein et al. suggested that in susceptible individuals,
the injection process per se could induce traumatic spasms
Fig. 1 Retinal image of a 74-year-old female patient (see Table 1)
who had undergone re-vitrectomy with retrobulbar anesthesia for a
persistent macular hole. Five days after the removal of the silicon oil
and its replacement with air, occlusion of the retinal artery was
revealed. The best visual acuity prior to the removal of the silicone oil
was 20/50; the final visual acuity (1 year after surgery) was 20/200
Fig. 2 Retinal image of a 66-year-old female patient (see Table 1)
who had undergone uncomplicated vitrectomy with retrobulbar
anesthesia for a macular hole using 15% SF6−gas filling. Occlusion
of the retinal artery occurred 2 days after surgery
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of the central retinal artery [3], in analogy to the finding
that stimulation of the retinal arterioles in cats can trigger a
vasospasm [6].
During the 3-month time-span of the published find-
ings, 141 patients have undergone vitrectomy in the same
context at our own center, the incidence of postoperative
vasoocclusive events among these individuals being 4.3%
(six patients). After the exclusion of obvious patient-
related factors and of irregularities in surgical devices and
machines including intra- and early postoperative IOP and
infusion flow, the commercial preparation of mepivacaine
(1% Scandicain®) was identified as a possible cause of
the vasoocclusive event. This local anesthetic contains
methyl- and propyl parahydroxybenzoate as preservatives.
The same local anesthetic, but in the absence of preserva-
tives, had been consistently used by the same surgeon
(specialized senior ophthalmologist) without encountering
a single instance of the complication in a total of almost
900 vitrectomies. No signs for inadvertent intrathecal
injection of the anesthetic could be found in our six
patients.
Astro Chemicals informed us that vascular occlusion and
neurotoxicity had been reported after an intrathecal appli-
cation of Scandicain®. Saiki et al. have discussed the
neurotoxic effects of the preservatives methyl- and propyl
parahydroxybenzoate, having observed cases of paraplegia
after the intrathecal application of chemotherapeutic drug
solutions containing these agents [7]. Previously, Nathan
and Sears had demonstrated that the topical application of a
0.1% solution of methyl hydroxybenzoate to the roots of
the spinal nerve induced a conduction blocking [8]. On the
basis of these disturbing indications, we filed a report to the
Swiss Health Authorities. In parallel to this action, Astro
Chemicals was compelled to include among the contra-
indications of Scandicain® a potential risk of vasoocclusion
in a retrobulbar application.
Interestingly, three of our six patients had undergone
retrobulbar anesthesia with Scandicain® 3–12 months
before the initial vitreoretinal intervention without evincing
clinically detectable signs of vascular occlusion. Therefore,
a long-lasting or even persistent toxic effect resulting in
cumulative toxicity can not be excluded.
Although we cannot categorically state that a correlation
exists between the presence of methyl- and propyl para-
hydroxybenzoate in solutions of mepivacaine and delayed
vascular occlusion after retrobulbar anesthesia, our findings
may suggest such an association. The 2- to 14-day time-
lapse between the induction of anesthesia and the onset of
vascular occlusion is indicative of a toxic effect on the
vascular endothelium rather than of a vasospastic event that
might be triggered by undetected intra- and early postop-
erative rises in IOP, which would be expected to occur
immediately.Ta
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In conclusion, the existing findings indicate a possible
vasculotoxic effect of preservatives included in commercial
preparations of mepivacaine. We thus strongly recommend
the use of preservative-free solutions of this local anesthetic
in ocular surgery.
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